{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:51:15Z","timestamp":1740178275495,"version":"3.37.3"},"reference-count":29,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venetoclax (VEN) is approved for relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a multicenter, retrospective cohort analysis comparing 321 CLL patients treated with VENmono vs VENcombo across the United States and the United Kingdom. We examined demographics, baseline characteristics, dosing, adverse events, response rates, and outcomes. The primary endpoints were progression-free survival (PFS) and overall survival (OS), estimated by Kaplan-Meier method, in patients treated with VENmono vs VENcombo. Univariate and bivariate analyses were performed with COX regression. Three hundred twenty-one CLL patients were included (3 median prior treatments, 78% prior ibrutinib). The overall response rates (ORRs) were similar (VENmono, 81% ORR, 34% complete remission [CR] vs VENcombo, 84% ORR, 32% CR). With a median follow-up of 13.4 months, no differences in PFS and OS were observed between the groups. In unadjusted analyses, the hazard ratios (HRs) for PFS and OS for VENmono vs VENcombo were HR 1.0 (95% confidence interval [CI], 0.6-1.8; P = .7) and HR 1.2 (95% CI, 0.6-2.3; P = .5), respectively. When adjusting for differences between the cohorts, the addition of an anti-CD20 antibody in combination with VEN did not impact PFS (HR, 1.0; 95% CI, 0.5-2.0; P = .9) or OS (HR, 1.1; 95% CI, 0.4-2.6; P = .8). We demonstrate comparable efficacy between VENmono and VENcombo in a heavily pretreated, high-risk, retrospective cohort, in terms of both response data and survival outcomes. Prospective studies are needed to validate these findings.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000180","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T20:55:13Z","timestamp":1558126513000},"page":"1568-1573","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R\/R CLL"],"prefix":"10.1182","volume":"3","author":[{"given":"Anthony R.","family":"Mato","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey E.","family":"Roeker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Cancer and Haematology Centre, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[{"name":"Aptitude Health, Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[{"name":"Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Cancer Center, Durham, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-3359","authenticated-orcid":false,"given":"Frederick","family":"Lansigan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Norris Cotton Cancer Center, Dartmouth University, Lebanon, NH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lombardi Cancer Center, Georgetown University, Washington, DC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-5951","authenticated-orcid":false,"given":"Arun K.","family":"Singavi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin Cancer Center, Milwaukee, WI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2787-3867","authenticated-orcid":false,"given":"Maryam Sarraf","family":"Yazdy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lombardi Cancer Center, Georgetown University, Washington, DC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin Cancer Center, Milwaukee, WI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-0899","authenticated-orcid":false,"given":"John N.","family":"Allan","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Weill Cornell Medical Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica B.","family":"Bhavsar","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Weill Cornell Medical Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin","family":"Kennard","sequence":"additional","affiliation":[{"name":"Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7042-5851","authenticated-orcid":false,"given":"AnnaLynn M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan P.","family":"Skarbnik","sequence":"additional","affiliation":[{"name":"Department of Medicine, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre H.","family":"Goy","sequence":"additional","affiliation":[{"name":"Department of Medicine, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Goodfriend","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Dorsey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina Cancer Center, Chapel Hill, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8458-9649","authenticated-orcid":false,"given":"Hande","family":"Tuncer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cancer Center, Tufts Medical Center, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitra S.","family":"Ujjani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison M.","family":"Winter","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Swedish Cancer Center, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Bailey","sequence":"additional","affiliation":[{"name":"Swedish Cancer Center, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[{"name":"Cancer and Haematology Centre, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2231-5527","authenticated-orcid":false,"given":"Andrea","family":"Sitlinger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Cancer Center, Durham, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Weissbrot","sequence":"additional","affiliation":[{"name":"Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5465-9562","authenticated-orcid":false,"given":"Sivraj","family":"Muralikrishnan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Norris Cotton Cancer Center, Dartmouth University, Lebanon, NH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-6883","authenticated-orcid":false,"given":"Andrew","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy A.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"Cancer Research UK & UCL Cancer Trials Centre, University College London, London, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-9254","authenticated-orcid":false,"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals, NHS Foundation Trust, Nottingham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"issue":"12","key":"2020021108291761100_B1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2020021108291761100_B2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2020021108291761100_B3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"2020021108291761100_B4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2020021108291761100_B5","article-title":"Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study [abstract]","volume":"35","author":"Sharman","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020021108291761100_B6","article-title":"Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL) [abstract]","volume":"130","author":"Burger","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021108291761100_B7","doi-asserted-by":"crossref","first-page":"Abstract 6","DOI":"10.1182\/blood-2018-99-116653","article-title":"Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): results of Alliance North American Intergroup Study A041202 [abstract]","volume":"132","author":"Woyach","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2020021108291761100_B8","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"2020021108291761100_B9","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020021108291761100_B10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.14447","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and\/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial","volume":"176","author":"Sharman","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"2020021108291761100_B11","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"19","key":"2020021108291761100_B12","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"2020021108291761100_B13","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"7172","key":"2020021108291761100_B14","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"issue":"15","key":"2020021108291761100_B15","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021108291761100_B16","doi-asserted-by":"crossref","first-page":"Abstract 4431","DOI":"10.1182\/blood-2018-99-113905","article-title":"Long term outcomes of venetoclax therapy for complex karyotype relapsed\/refractory chronic lymphocytic leukemia [abstract]","volume":"132","author":"Lew","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021108291761100_B17","first-page":"Abstract 4329","article-title":"Impact of number of prior therapies and bulk of disease on outcomes with venetoclax (VEN) monotherapy for relapsed\/refractory chronic lymphocytic leukemia (CLL) [abstract]","volume":"130","author":"Wierda","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2020021108291761100_B18","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinico-pathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021108291761100_B19","first-page":"Abstract 432","article-title":"Acalabrutinib with obinutuzumab in relapsed\/refractory and treatment-naive patients with chronic lymphocytic leukemia: the phase 1b\/2 ACE-CL-003 Study [abstract]","volume":"130","author":"Woyach","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2020021108291761100_B20","doi-asserted-by":"crossref","first-page":"Abstract 1660","DOI":"10.1182\/blood.V118.21.1660.1660","article-title":"LFB-R603, a third-generation monoclonal anti-CD20 antibody displays an additive antitumor activity with antileukemic chemotherapeutic agents in mouse xenograft models [abstract]","volume":"118","author":"Esteves","year":"2011","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021108291761100_B21","first-page":"Abstract 430","article-title":"Safety, efficacy and MRD negativity of a combination of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia\u2014results from a phase 1b study (GP28331) [abstract]","volume":"130","author":"Flinn","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2020021108291761100_B22","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2017-01-761973","article-title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","volume":"129","author":"Fischer","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2020021108291761100_B23","doi-asserted-by":"crossref","first-page":"Abstract 496","DOI":"10.1182\/blood.V126.23.496.496","article-title":"Results of the safety run-in phase of CLL14 (BO25323): a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and venetoclax (GDC-0199\/ABT-199) with obinutuzumab and chlorambucil in patients with previously untreated CLL and coexisting medical conditions [abstract]","volume":"126","author":"Fischer","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2020021108291761100_B24","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1470-2045(18)30414-5","article-title":"Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Cramer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"2020021108291761100_B25","doi-asserted-by":"crossref","first-page":"Abstract 7502","DOI":"10.1200\/JCO.2018.36.15_suppl.7502","article-title":"Phase 2 CAPTIVATE results of ibrutinib (IBR) plus venetoclax (VEN) in first-line chronic lymphocytic leukemia (CLL) [abstract]","volume":"36","author":"Wierda","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020021108291761100_B26","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2018-05-853564","article-title":"Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia","volume":"132","author":"Rogers","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2020021108291761100_B27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2020021108291761100_B28","doi-asserted-by":"crossref","first-page":"Abstract LBA-2","DOI":"10.1182\/blood.V130.Suppl_1.LBA-2.LBA-2","article-title":"Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\u2014results from pre-planned interim analysis of the randomized phase 3 Murano Study [abstract]","volume":"130","author":"Seymour","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020021108291761100_B29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2018-08-869503","article-title":"Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?","volume":"133","author":"Sarraf Yazdy","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/10\/1568\/1632327\/advancesadv2019000180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/10\/1568\/1632327\/advancesadv2019000180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T06:12:00Z","timestamp":1663481520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/10\/1568\/246640\/A-retrospective-comparison-of-venetoclax-alone-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000180","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2019,5,17]]}}}